Decoding the Science of Life
The FDA has approved atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant treatment for completely resected stage III deficient mismatch…
The FDA’s October 1 approval of Edwards Lifesciences’ AUTUS Size-Adjustable Valve is a real pediatric-device inflection point, not simply a…
NeuroAI is often framed as whether a system can “understand” a person. That framing is too loose for a product…
Octant has reached a meaningful but early clinical threshold in inherited retinal disease. The company announced first-patient dosing in the…
Longeveron’s September 16 readout from ELPIS II provides a demanding but important lesson in clinical-trial interpretation. The Phase 2b study…
Skyhawk Therapeutics’ September 15 release on SKY-0515 offers an unusually detailed early clinical picture for Huntington’s disease. The company reported…
Amgen announced on September 14 that the FDA approved an update to the prescribing information for IMDELLTRA, or tarlatamab-dlle, that…
BrainLayer is applying a NeuroAI-enabled Human Model to Physical AI, with an evidence-first approach to human-state data, robotics recovery, and…
The FDA has expanded the accelerated approval of sevabertinib, marketed as Hyrnuo, for adults with locally advanced or metastatic non-squamous…
BridgeBio has reported new exploratory analyses from PROPEL 3, its Phase 3 study of oral infigratinib in children with achondroplasia.…
Leyden Laboratories has reported positive Phase 1 findings for RIG-101, an investigational intranasal innate-immune modulator intended to strengthen antiviral defenses…
